NIH will also not enroll new patients in any of the affected trails until the problems are resolved, but there is no evidence that any patients have been harmed.
The affected facilities are a National Cancer Institute lab that makes cell therapy products and a National Institute of Mental Health lab that makes positron emission tomography, or PET, materials.
NIH had hired two companies to evaluate all of its facilities that produce sterile or infused products after major issues at the NIH Clinical Center Pharmaceutical Development Section were found last year.
According to NPR, NIH also launched an internal investigation after the problems last year and put together a so-called “red team” to find the underlying cause of safety issues. The team is set to brief an advisory committee Thursday.
More articles on patient safety:
Theranos CEO says she is ‘devastated’ issues weren’t caught sooner
CDC worker possibly infected with laboratory-acquired Salmonella
CDC’s 6 public health threats in focus for 2016
